-
Posted by
Two Blokes Jul 30 -
Filed in
Stock
-
3 views
Novo Nordisk's stock has dropped over 20%, but its core business remains strong and diversified, making this an attractive entry point for investors. Despite increased GLP-1 competition and lowered guidance, Novo Nordisk continues to grow, expand its market share, and generate robust cash flow. The company's rare disease and oral semaglutide segments are showing promising growth, with a strong R&D pipeline supporting future expansion.
